Sonnet BioTherapeutics | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

28 March 2024

Xilio gets a Gilead-shaped reprieve

A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.

Deals

19 December 2023

Compugen’s novel cytokine approach gets Gilead buy-in

Subscribe to Sonnet BioTherapeutics